Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

NVCT

Phase 1b

NXP800

Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Q2 2025

Initiated trial in Q1 2023. 3/14/24- Prelim data reported at AACR '24. 8/29/24- Granted Orphan Drug Designation. 11/14/24- Interim data reported w/ additional clinical data in Q2 2025.

Data readout

PRTA

Phase 3

Birtamimab

AL Amyloidosis (Amyloid light chain)

Q2 2025

Suspected Mover: AFFIRM-AL study. 1/8/24 Enrollment remains on track. 11/12/24- Topline data in Q2 2025.

Data readout

PYPD

Phase 3

D-PLEX-100

Abdominal colorectal surgical site infections

Q2 2025

SHIELD II study.11/13/24- Unblinded interim analysis later in Q4 2024. 2/12/25- Enrollment completion in March 2025 w/ topline results in Q2 2025.

Data readout

VIGL

Phase 2

Iluzanebart (VGL101)

ALSP (Adult onset leukoencephalopathy w/ axonal spheroids & pigmented glia)

Q2 2025

IGNITE trial. 4/17/24- Presented interim data at AAN '24. 3/13/25- Report final analysis in Q2 2025.

Data Readout

PRTA

Phase 2

Coramitug (PRX004)

ATTR Amyloidosis

H1 2025

Collab w/ Novo Nordisk. 11/12/24- Completed enrollment w/ topline data in H1 2025.

Data readout

CTMX

Phase 1a

CX-2051

Advanced metastatic colorectal cancer (CRC)

H1 2025

1/24/24- IND cleared. 4/24- First patient dosed. 3/6/25- Initial data in H1 2025.

Data readout

CRDL

Phase 2

CardiolRx™

Myocarditis

Q2 2025

Suspected Mover: ARCHER trial. 9/24/24- Achieved target patient enrollment. 3/25- Topline data in Q2 2025. Full data presentation at a scientific meeting in H2 2025.

Data readout

DMAC

Phase 2

DM199 (KLK1 protein)

Preeclampsia

Q2 2025

Ph2 Investor sponsored trial. 10/9/24- Received IND clearance. 11/13/24- Dosed first patient. Topline data in Q2 2025.

Data readout

TIL

Phase 1

AXN-2510 (formerly SYN-2510) /IMM2510

Relapsed or refractory (R/R) Non-Small Cell Lung Cancer (NSCLC), solid tumor/s

H1 2025

3/4/25- Safety data in H1 2025.

Data readout

VERA

Phase 3

Atacicept

IgAN (IgA Nephropathy)

Q2 2025

ORIGIN, PIONEER studies. 1/25/24- Presented Ph2b 72-week data. 10/28/24- Presented 96-wk data at ASN '24. 2/26/25- Full enrollment and primary endpoint results in Q2 2025. BLA submission in H2 2025. Initiate PIONEER study in 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20